Full-Time

Creative Strategist

Eucalyptus

Eucalyptus

501-1,000 employees

Global telehealth platform offering digital clinics

No salary listed

Toronto, ON, Canada

Remote

Category
Growth & Marketing (2)
,

Get referred to Eucalyptus

See people who can refer or advise you

Requirements
  • At least 5 years of experience in creative strategy, performance marketing, advertising, content strategy, copywriting, or a related discipline.
  • A portfolio or body of work demonstrating contributions to performance creative, including concepts, briefs, scripts, campaigns, or testing programs.
  • Strong understanding of consumer behaviour, advertising psychology, and the factors that make creative capture attention and drive action.
  • Experience developing creative for paid social and video channels, particularly Meta and YouTube.
  • Ability to interpret advertising performance and connect results to specific creative variables.
  • Strong writing and communication skills, including the ability to turn an insight into a compelling concept and provide precise, constructive feedback.
  • Experience collaborating with designers, editors, media buyers, creators, agencies, or production partners.
  • Structured approach to experimentation, including articulating hypotheses, isolating meaningful variables, evaluating results, and deciding what to test next.
  • Ability to operate autonomously, make progress through ambiguity, and balance thoughtful analysis with a bias toward action.
  • Genuine curiosity about using artificial intelligence to improve how creative work is researched, developed, and evaluated.
Responsibilities
  • Own the creative strategy and testing roadmap across Meta, YouTube, and other growth channels, with opportunities to extend successful ideas into television, out-of-home, and emerging formats.
  • Turn customer research, cultural observations, competitive intelligence, and performance data into creative hypotheses and campaign concepts.
  • Write and refine creative briefs, hooks, scripts, messaging frameworks, and visual direction tailored to the customer, platform, and stage of awareness.
  • Lead weekly creative performance reviews, connecting thumb-stop rate, click-through rate, conversion rate, customer acquisition cost, and creative fatigue to recommendations for the next round of testing.
  • Guide concepts from brief through launch and iteration, providing actionable feedback to designers, editors, creators, agencies, and media buyers.
  • Partner with Brand, Legal, Clinical, and Regulatory teams to develop creative that earns customer trust and meets regulated healthcare standards.
  • Build and maintain creative playbooks, testing frameworks, and a structured repository of learnings.
  • Use artificial intelligence to accelerate research synthesis, concept exploration, script development, creative variation, and analysis without compromising originality or judgment.
  • Monitor platform behaviour, advertising formats, cultural conversations, and competitor activity to identify opportunities for the Canadian market.
Desired Qualifications
  • Experience in healthcare, subscriptions, direct-to-consumer businesses, or another regulated, high-consideration, or trust-based category.
  • Experience adapting creative strategy for Canadian or Quebec audiences.
  • Professional proficiency in both English and French.
  • Experience with creator-led, testimonial, user-generated-content-style, television, or out-of-home advertising.

Eucalyptus.vc runs digital healthcare clinics as a global telehealth service focused on patient-first care. Patients connect with certified practitioners for remote consultations, treatments, and ongoing care entirely through the online platform. The service provides end-to-end care in one digital ecosystem, from initial visit to follow-up, with revenue from fees for these clinical services. The company aims to make safe, effective care accessible worldwide by leveraging its global team of over 400 professionals to operate the clinics.

Company Size

501-1,000

Company Stage

Acquired

Total Funding

$139.7M

Headquarters

Sydney, Australia

Founded

2019

Get referred to Eucalyptus

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Hims & Hers closed the acquisition on 2026-06-02, validating Eucalyptus's scale.
  • Run-rate revenue exceeded $450 million and 2025 growth stayed triple-digit.
  • Consultmed referrals launched in March 2026, expanding GP-sourced Juniper demand.

What critics are saying

  • Hims & Hers bought Eucalyptus on 2026-02-19, ending standalone employer upside.
  • Earnouts through early 2029 tie employee value to Hims & Hers targets.
  • Telehealth weight-loss rivals and regulators can crush Juniper margins quickly.

What makes Eucalyptus unique

  • Juniper and Pilot give Eucalyptus category-specific consumer brands across five countries.
  • Tim Doyle built local regulatory playbooks, enabling Hims & Hers' June 2026 integration.
  • ACHS accreditation and 20+ outcome studies signal clinically disciplined operations.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Employee Stock Purchase Plan

Flexible Work Hours

Hybrid Work Options

Wellness Program

Mental Health Support

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Stock Options

Company Equity

Conference Attendance Budget

Professional Development Budget

Birthdays?

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

3%

2 year growth

-3%
Schaeffer's Investment Research
Feb 20th, 2026
Geopolitical Tensions Resurface Amid Volatile Week

Geopolitical tensions resurface amid volatile week. The S&P 500 and Nasdaq boast healthy weekly gains. Assistant Editor Feb 20, 2026 at 2:09 PM Despite Tuesday's rough start, all three major indexes closed higher, the Nasdaq Composite (IXIC) snapping its four day-losing streak. Stocks held steady on Wednesday after receiving a boost from big tech gains, while the Federal Reserve's January meeting minutes held investor attention. On Thursday, the Dow Jones Industrial Average (DJI) and S&P 500 Index (SPX) both snapped three-day win streaks, while the Nasdaq also faced trouble; these losses slid right past traders as focus remained on geopolitical tensions and weekly jobless claims. The Nasdaq and S&P 500 are pacing for weekly gains, after the Supreme Court dismissed President Donald Trump's tariffs and lifted Wall Street's spirits. Stock movers this week. There were plenty of headlines for investors to unpack over the holiday-shortened week. Norwegian Cruise Line Holdings (NCLH) popped after reports that Elliott Investment Management has built an over 10% stake. In M&A news, Masimo (MASI) stock soared after reports that it will be acquired by Danaher (DHR) for $10 billion, while Hims & Hers Health (HIMS) announced its $1.15 billion acquisition of Australian digital health company Eucalyptus. In biotech news this week, the U.S. Food & Drug Administration (FDA) accepted Moderna's (MRNA) flu vaccine application for review, while Grail (GRAL) stock plummeted after the company's three-year cancer screening trial failed to meet its main goal. Meanwhile, Walmart's (WMT) disappointed earnings outlook contributed to pessimism on Thursday. Commodities, rare earths in focus. Rising oil prices were a highlight this week amid U.S.-Iran tensions, with options bulls targeting the United States Oil Fund (USO). Meanwhile, Devon Energy (DVN) tapped a 17-month high after strong fourth-quarter results, while Melius Research upgraded Chevon (CVX), citing exploration upside. Even further, gold mining name Newmont (NEM) continued to charge higher before its fourth-quarter report. On the flip side, rare earths stock MP Materials (MP) plummeted to a one-month low. As goes february. The final week of the month is jam packed with key earnings reports, delayed economic data, speeches from several Federal Reserve officials, and more. For now, Schaeffer's Senior V.P. of Research Todd Salamone says to keep your eye on these S&P 500 names, while Senior Quantitative Analyst Rocky White breaks down Wall Street's "fear gauge."

The Wall Street Journal
Feb 19th, 2026
Hims & Hers to Acquire Eucalyptus in $1.15 Billion Deal

Hims & Hers Health has agreed to acquire digital health company Eucalyptus in a deal valued at $1.15 billion in an effort to expand its geographic reach.

Investing.com
Feb 19th, 2026
Hims & Hers stock rises after agreement to acquire Eucalyptus

Hims & Hers stock rises after agreement to acquire Eucalyptus. ByInvesting.com Published 02/19/2026, 06:54 AM (C) Reuters. Investing.com - Hims & Hers Health, Inc. (NYSE:HIMS) stock rose 7.8% Thursday morning after the company announced it has entered into a definitive agreement to acquire Eucalyptus, an international digital health leader with operations in Australia, the UK, Germany, Japan, and Canada. The acquisition, valued at up to $1.15 billion USD, will accelerate Hims & Hers' global expansion strategy while preserving its financial flexibility. The company will pay approximately $240 million in cash upon closing, with the remaining consideration structured as deferred payments over 18 months and additional earnout payments tied to financial targets through early 2029. Eucalyptus, which operates consumer brands including Juniper and Pilot, has served more than 775,000 customers and currently maintains an annual revenue run-rate exceeding $450 million USD. The company has demonstrated triple-digit YoY revenue growth in each quarter of calendar year 2025 while operating near profitability. "Healthcare challenges are global, and so is the demand for simpler, transparent, and more personalized healthcare," said Andrew Dudum, founder and CEO of Hims & Hers. "With Eucalyptus, we will not only enter new markets, we will expand our ability to serve customers globally, trusting local experts to be a key part of how we transform healthcare into a customer-first, personalized industry." Following the acquisition's completion, Eucalyptus CEO Tim Doyle will become SVP of International at Hims & Hers, overseeing the company's international business. Eucalyptus' portfolio of brands will transition into Hims & Hers over time. The transaction is expected to close during the middle of calendar year 2026, subject to regulatory approvals and other customary closing conditions. Hims & Hers plans to finance most of the acquisition using existing cash and future operating cash flows from its U.S. operations. Which stock should you buy in your very next trade? AI computing powers are changing the stock market. Investing.com's ProPicks AI includes dozens of winning stock portfolios chosen by our advanced AI. Year to date, 2 out of 3 global portfolios are beating their benchmark indexes, with 88% in the green. Our flagship Tech Titans strategy doubled the S&P 500 within 18 months, including notable winners like Super Micro Computer (+185%) and AppLovin (+157%). Which stock will be the next to soar?

PR Newswire
Jul 28th, 2025
Amigo Partners with Eucalyptus to Scale AI-Powered Healthcare Delivery Across Global Telehealth Network

Amigo partners with Eucalyptus to scale ai-powered healthcare delivery across global telehealth network.

PR Newswire
Feb 4th, 2025
Lorikeet Secures $9M for AI Expansion

Lorikeet, an AI customer experience company, has secured an additional AUD 9 million in funding from Blackbird and existing investors, following a USD 5 million seed round last year. The funds will enhance Lorikeet's platform and expand its market presence in industries like healthcare and finance. Lorikeet's intelligent graph technology enables AI agents to handle complex support queries, improving customer satisfaction and support efficiency for clients like Eucalyptus and Magic Eden.